Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
Status:
Recruiting
Trial end date:
2029-10-14
Target enrollment:
Participant gender:
Summary
This is a prospective, open, single-center, single-arm phase II clinical study with common
EGFR-sensitive mutations (Ex19del and L858R) identified in the central laboratory.To evaluate
the efficacy and safety of adjuvant Osimertinib therapy in completely resected stage I
non-squamous non-small cell lung cancer (NSCLC) with high-risk factors (solid and/or
micropapillary component ≥10%, and/or airway spread).
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital